Filing Flows › Alamar Biosciences (ALMR) › Q3 2026 › vs Q3 2025
Alamar Biosciences (ALMR) Q3 2026 vs Q3 2025 (year over year)
Alamar Biosciences's revenue rose $13.6M (+68%) from $19.9M in Q3 2025 to $33.5M in Q3 2026. The biggest changes: Product +$10.7M (+68%); Service Other +$3.0M (+69%).
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $17.8M | $10.0M | $7.9M | +79% |
| Instruments | $8.5M | $5.7M | $2.8M | +50% |
| Product | $26.3M | $15.6M | $10.7M | +68% |
| Service Other | $7.2M | $4.3M | $3.0M | +69% |
| Revenue | $33.5M | $19.9M | $13.6M | +68% |
| Other income, net | $1.9M | $324K | $1.6M | +484% |
| Net loss | $13.3M | $8.0M | $5.3M | +67% |
| Costs & expenses | $48.8M | $28.2M | $20.5M | +73% |
| Operating costs | $48.7M | $27.8M | $20.9M | +75% |
| Income tax | $94K | $440K | −$346K | -79% |
| Cost of revenue | $12.9M | $8.0M | $4.9M | +61% |
| Research & development | $16.2M | $10.2M | $6.0M | +58% |
| SG&A | $19.6M | $9.6M | $10.0M | +105% |
| Operating cash sources | $20.1M | $15.8M | $4.2M | +27% |
| Depreciation & amortization | $1.4M | $983K | $441K | +45% |
| Share-based compensation | $3.9M | $705K | $3.2M | +455% |
| Cash used in operations | $14.7M | $14.1M | $593K | +4% |
| Net loss absorbed | $13.3M | $8.0M | $5.3M | +67% |
| Working capital & other | $6.7M | $7.8M | −$1.1M | -14% |
Questions
How much did Alamar Biosciences's revenue grow year over year in Q3 2026?
Alamar Biosciences's revenue rose $13.6M (+68%) from $19.9M in Q3 2025 to $33.5M in Q3 2026.
What drove Alamar Biosciences's revenue change in Q3 2026?
Product +$10.7M (+68%); Service Other +$3.0M (+69%).